Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS)
- PMID: 20869848
- PMCID: PMC2981616
- DOI: 10.1016/j.schres.2010.08.039
Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS)
Abstract
As part of an ongoing scale development process, this study provides an initial examination of the psychometric properties and validity of a new interview-based negative symptom instrument, the Clinical Assessment Interview for Negative Symptoms (CAINS), in outpatients with schizophrenia or schizoaffective disorder (N = 37). The scale was designed to address limitations of existing measures and to comprehensively assess five consensus-based negative symptoms: asociality, avolition, anhedonia (consummatory and anticipatory), affective flattening, and alogia. Results indicated satisfactory internal consistency reliability for the total CAINS scale score and promising inter-rater agreement, with clear areas identified in need of improvement. Convergent validity was evident in general agreement between the CAINS and alternative negative symptom measures. Further, CAINS subscales significantly correlated with relevant self-report emotional experience measures as well as with social functioning. Discriminant validity of the CAINS was strongly supported by its small, non-significant relations with positive symptoms, general psychiatric symptoms, and depression. These preliminary data on an early beta-version of the CAINS provide initial support for this new assessment approach to negative symptoms and suggest directions for further scale development.
Copyright © 2010 Elsevier B.V. All rights reserved.
Conflict of interest statement
Dr. Blanchard has received honorarium from Merck for consultation. Dr. Gur has received investigator initiated grants from Astra Zeneca and Pfizer; honorarium from Astra Zeneca and Pfizer for a lecture and from Merck for consultation.
Similar articles
-
The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation.Am J Psychiatry. 2013 Feb;170(2):165-72. doi: 10.1176/appi.ajp.2012.12010109. Am J Psychiatry. 2013. PMID: 23377637 Free PMC article.
-
Validation of the German version of the Clinical Assessment Interview for Negative Symptoms (CAINS).Psychiatry Res. 2014 Dec 15;220(1-2):659-63. doi: 10.1016/j.psychres.2014.07.070. Epub 2014 Aug 1. Psychiatry Res. 2014. PMID: 25138895
-
Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS).Schizophr Res. 2011 Nov;132(2-3):140-5. doi: 10.1016/j.schres.2011.06.030. Epub 2011 Jul 27. Schizophr Res. 2011. PMID: 21798716 Free PMC article.
-
The brief negative symptom scale in translation: A review of psychometric properties and beyond.Eur Neuropsychopharmacol. 2020 Apr;33:36-44. doi: 10.1016/j.euroneuro.2020.01.018. Epub 2020 Feb 18. Eur Neuropsychopharmacol. 2020. PMID: 32081498 Review.
-
Clinical Assessment Interview for Negative Symptoms (CAINS): A Systematic Review of Measurement Properties.Schizophr Bull. 2024 Jul 27;50(4):747-756. doi: 10.1093/schbul/sbad137. Schizophr Bull. 2024. PMID: 37951838 Free PMC article.
Cited by
-
Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale.Schizophr Res. 2012 Dec;142(1-3):88-92. doi: 10.1016/j.schres.2012.10.012. Epub 2012 Nov 3. Schizophr Res. 2012. PMID: 23127378 Free PMC article.
-
Psychometric evaluation of the negative syndrome of schizophrenia.Eur Arch Psychiatry Clin Neurosci. 2015 Oct;265(7):559-66. doi: 10.1007/s00406-015-0595-z. Epub 2015 Mar 24. Eur Arch Psychiatry Clin Neurosci. 2015. PMID: 25802109 Review.
-
Validation of accelerometry as a digital phenotyping measure of negative symptoms in schizophrenia.Schizophrenia (Heidelb). 2022 Apr 15;8(1):37. doi: 10.1038/s41537-022-00241-z. Schizophrenia (Heidelb). 2022. PMID: 35853890 Free PMC article.
-
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape.CNS Drugs. 2025 Mar;39(3):243-262. doi: 10.1007/s40263-024-01151-7. Epub 2025 Jan 12. CNS Drugs. 2025. PMID: 39799532 Review.
-
The Brief negative Symptom Scale (BNSS): a systematic review of measurement properties.Schizophrenia (Heidelb). 2023 Jul 27;9(1):45. doi: 10.1038/s41537-023-00380-x. Schizophrenia (Heidelb). 2023. PMID: 37500628 Free PMC article. Review.
References
-
- Addington D, Addington J, Atkinson M. A psychometric comparison of the Calgary depression scale for schizophrenia and the Hamilton depression rating scale. Schizophr Res. 1996;19:205–212. - PubMed
-
- Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3:247–251. - PubMed
-
- Alphs LD, Summerfelt A, Lann H, Muller RJ. The negative symptom assessment: a new instrument to assess negative symptoms in schizophrenia. Psychopharmacol Bull. 1989;25:159–163. - PubMed
-
- Andreasen NC. Negative symptoms in schizophrenia: Definition and reliability. Arch Gen Psychiatry. 1982;39:784–788. - PubMed
-
- Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS) Iowa City, IA: The University of Iowa; 1984.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials